You have no items in your shopping cart.
On Promotion
Elisa Kits Promotion 1
Products on Sale 0
Category
Antibodies 1300
Proteins and Peptides 1287
Small Molecules 322
Tools 74
Assays and Kits 43
Species Host
Rabbit 388
Mouse 269
Human 160
Goat 30
E. coli 28
Mammal 24
Plant 8
Camelus 6
Gallus 1
Tested Applications
ELISA 1085
WB 670
IF 120
EIA 57
IHC 55
NeA 53
Blocking 50
FC 50
SDS-PAGE 36
Kinetics 33
MS 32
IHC-P 23
IP 19
LF 14
GICA 11
ICC 11
CLIA 8
Functional Studies 7
IA 7
In vivo 6
Crystallography 5
Control 4
DOT 4
IHC-Fr 3
FA 2
FACS 2
Reactivity
Virus 852
Human 186
Other 55
Mouse 52
Rat 19
Hamster 3
Primate 2
All 1
Camelus 1
Predicted Reactivity
Virus 134
Bovine 6
Canine 1
Equine 1
Guinea 1
Mouse 1
Pig 1
Rabbit 1
Rat 1
Zebrafish 1
Conjugation
Unconjugated 1060
Biotin 69
HRP 62
AP 31
PE 17
FITC 16
APC 15
Cy3 15
iFluor647 14
AE 7
IRDye800 4
APC/Cy5.5 1
APC/Cy7 1
BF350 1
BF405 1
BF488 1
BF555 1
BF594 1
BF647 1
BF680 1
BF750 1
Cy5 1
Cy5.5 1
Cy7 1
PE/Cy5 1
PE/Cy5.5 1
PE/Cy7 1
PerCP 1
PerCP/Cy5.5 1
PerCP/Cy7 1
RBITC 1
Clonality
Monoclonal 660
Polyclonal 453
Recombinant 178
Matched Antibody
Yes 0
No 3026
Featured Product
Yes 355
Has Publications
Yes 1
No 3025
Search results for: 'Cov'
98.00%
26.52 kDa (predicted); 33.2 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (C.36.3) Spike RBD (YP_009724390.1, with mutation R346S, L452R) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.36.3). Predicted N terminal: Arg 319
C-His
100 μg98.00%
26.71 kDa (predicted); 36.55 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529 sublineage BA.2). Predicted N terminal: Arg 319
C-His
100 μg98.00%
134.54 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
136.29 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (EG.5.1) Spike S1+S2 (YP_009724390.1, with mutations T19I, L24S, del25-27, Q52H, V83A, G142D, del144, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, F456L, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant EG.5.1). Predicted N terminal: Val 16
C-His
100 μg98.00%
25.36 kDa (predicted); 38.8 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.86) Spike RBD (YP_009724390.1, with mutation I332V, G339H, K356T, S371F, S373P, S375F, T376A, R403K, D405N, R408S, K417N, N440K, V445H, G446S, N450D, L452W, N460K, S477N, T478K, N481K, V483del, E484K, F486P, Q498R, N501Y, Y505H) (Arg319-Lys529) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.86). Predicted N terminal: Arg 319
C-His
100 μg98.00%
28.41 kDa (predicted); 37.65 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations K417N, L452R, T478K) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. The mutations were identified in the SARS-CoV-2 variant (known as variant (AY.1/AY.2)) which emerged in the India. Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
25.20 kDa (predicted); 25.20 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1) (Arg319-Lys529) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Arg 319
C-His
100 μg98.00%
26.60 kDa (predicted); 31.68 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations K417N, L452R, T478K) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant (AY.1/AY.2)) which emerged in the India. Predicted N terminal: Arg 319
C-His
100 μg98.00%
26.50 kDa (predicted); 33.47 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452Q, F490S) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.37) which emerged in the Peru. Predicted N terminal: Arg 319
C-His
100 μg98.00%
26.57 kDa (predicted); 36.95 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations S477N, E484K) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant (B.1.526) which emerged in the United States of America. Predicted N terminal: Arg 319
C-His
100 μg